Clinical trials
Completed Gastroesophageal Reflux trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
679 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 9 |
| 2002 | 11 |
| 2003 | 11 |
| 2004 | 22 |
| 2005 | 40 |
| 2006 | 45 |
| 2007 | 33 |
| 2008 | 54 |
| 2009 | 39 |
| 2010 | 46 |
| 2011 | 23 |
| 2012 | 29 |
| 2013 | 35 |
| 2014 | 27 |
| 2015 | 19 |
| 2016 | 30 |
| 2017 | 35 |
| 2018 | 26 |
| 2019 | 15 |
| 2020 | 21 |
| 2021 | 19 |
| 2022 | 30 |
| 2023 | 17 |
| 2024 | 13 |
| 2025 | 12 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 679 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 85 |
| Takeda | 29 |
| Mayo Clinic | 20 |
| Eisai Inc. | 8 |
| Seoul National University Hospital | 8 |
| University of North Carolina, Chapel Hill | 8 |
| Wyeth is now a wholly owned subsidiary of Pfizer | 8 |
| Universitaire Ziekenhuizen KU Leuven | 7 |
| Asian Institute of Gastroenterology, India | 6 |
| Chong Kun Dang Pharmaceutical | 6 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Gastroesophageal Reflux | 679 |
| Heartburn | 66 |
| Barrett Esophagus | 35 |
| Esophagitis | 19 |
| Obesity | 19 |
| Dyspepsia | 18 |
| Esophagitis, Peptic | 15 |
| Hernia, Hiatal | 15 |
| Asthma | 13 |
| Deglutition Disorders | 13 |
Trials
Showing 1 to 25 of 679. Each trial links to its page on Pharma Observatory.
579 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.